Geom Seog Seo 4 Department of Internal Medicine, Digestive Disease Research Institute, Wonkwang University Hospital, Wonkwang University College of Medicine, Iksan, Korea Find articles by Geom Seog Seo

Laterally spreading colorectal tumors (LSTs) are divided into four subtypes, including homogenous (HG), nodular mixed (NM), flat elevated (FE), and pseudo-depressed (PD), based on their different endoscopic morphologies.

Geom Seog Seo's 135 research works with 2,785 citations and 6,821 reads, including: Gastrointestinal Stromal Tumor of Small Intestine

In this study, we will conduct a retrospective review of the outcomes and long-term prognosis of endoscopic treatment on type 3 gastric NETs. In addition, we demonstrate the efficacy of endoscopic treatment on type 3 gastric NETs. This work has been carried out in accordance with the Declaration of Helsinki (2000) of the World Medical Association.

Jan 8, 2013 · Author contributions: Geom Seog Seo, Young-Eun Joo, Gwang Ha Kim, Gwang Ho Baik, Jeong Eun Shin, Heung Up Kim and Nayoung Kim made substantial contribution to the conception and design of the study, the acquistion of the data and analysis and interpretation of the data, and wrote the paper.

최근에 염증성 장질환의 유전학적 연구에 있어 인간 게놈 (Genome)의 기본 시퀀스(sequence) 및 구조에 대한 연구가 이 루어지고 있으며 향상된 DNA 분석 검사 기술(genotyping tech-nology), 통계 기술 및 생물정보학(bioinformatics)발전, 국가 간 협력을 통한 정보 공유 등을 통해 전환점을 맞이하고 있 고 유전자와 염증성 장질환을 연관시켜 분석하는 최신방법 인 게놈범주관련(Genome-wide association: GWA)연구를 통 해 새로운 관련 유전자가 발견되고 있다(표 1).

Colonic diverticular disease is the common conditions in industrialized and westernized countries, but it is relatively rare in areas such as Asia. Colonic diverticula are asymptomatic in most cases, only 10-25% develop diverticulitis and 1% finally gets surgery.

Oct 7, 2014 · Of the diverse biological agents used for patients with ulcerative colitis, the anti-tumor necrosis factor-α agents infliximab and adalimumab have been used in large-scale clinical trials and are currently widely used in the treatment of inflammatory bowel disease patients.

Current Concepts: Vedolizumab, a gut-selective agent that targets α4β7 integrin is effective in both ulcerative colitis and Crohn’s disease. Ustekinumab is a monoclonal antibody that binds to p40 subunit of interleukin-12/interleukin-23. Ustekinumab is available for the treatment of Crohn’s disease and ulcerative colitis.

We aimed to find the predictive factors associated with technical difficulty in colorectal ESD before the procedure. Clinical data from patients who underwent ESD for colorectal tumors in 5 hospitals in Honam province of South Korea between 2015 and 2020 were reviewed retrospectively.